Literature DB >> 1310552

The E7 functions of human papillomaviruses in rat 3Y1 cells.

S Watanabe1, H Sato, N Komiyama, T Kanda, K Yoshiike.   

Abstract

Among more than 60 human papillomavirus (HPV) genotypes, several HPVs are believed to be high risk because they are found in close association with cervical carcinoma. We compared the E7 genes from HPVs 1, 6b, 16, 18, and 33 for their transactivating, transforming, and mitogenic functions in a single cell line rat 3Y1. Whereas both the low-risk (1 and 6b) and the high-risk (16, 18, and 33) HPVs were transactivating for the adenovirus E2 promoter, only the high-risk HPVs were capable of focal transformation as assayed by an efficient method using the SR alpha-promoter and in conjunction with the HPV 16 E6 gene. The putative oncogenicity of HPVs appears to be reflected in vitro by the focal transformation, but not by the transactivation. Transient expression of the E7 genes controlled by the dexamethasone-responsive MMTV-LTR showed that the HPV 16 mutant E7s only with residual transforming activity were not mitogenic, but that, although the low-risk HPV E7s were less efficient, both the low-risk and high-risk HPV E7s were capable of inducing cellular DNA synthesis. Probably, the capability to induce cell DNA synthesis is necessary but not sufficient for the E7-mediated focal transformation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310552     DOI: 10.1016/0042-6822(92)90299-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  E7 proteins of four groups of human papillomaviruses, irrespective of their tissue tropism or cancer association, possess the ability to transactivate transcriptional promoters E2F site dependently.

Authors:  A Hiraiwa; T Kiyono; S Suzuki; M Ohashi; M Ishibashi
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

3.  Green tea compound in chemoprevention of cervical cancer.

Authors:  Changping Zou; Huaguang Liu; Jean M Feugang; Zhengping Hao; H-H Sherry Chow; Francisco Garcia
Journal:  Int J Gynecol Cancer       Date:  2010-05       Impact factor: 3.437

4.  The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein.

Authors:  E W Wu; K E Clemens; D V Heck; K Münger
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

5.  Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E.

Authors:  L G Martin; G W Demers; D A Galloway
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Papilloma formation by cottontail rabbit papillomavirus requires E1 and E2 regulatory genes in addition to E6 and E7 transforming genes.

Authors:  X Wu; W Xiao; J L Brandsma
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1.

Authors:  A Schmitt; J B Harry; B Rapp; F O Wettstein; T Iftner
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

Review 8.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

9.  Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation.

Authors:  G W Demers; E Espling; J B Harry; B G Etscheid; D A Galloway
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes.

Authors:  E W Lam; J D Morris; R Davies; T Crook; R J Watson; K H Vousden
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.